Chronic hepatitis C with genotype 2a/2b or genotype 1b and low viral load (<
Conditions
Interventions
PEG-IFN alpha-2a weekly for 24 weeks in patients with negative results of HCV RNA test at week 4 of therapy (Group A)
PEG-IFN alpha-2a weekly for 48 weeks in patients with negative results of HCV RNA
Sponsors
Japanese Consortium for the Study of Liver Diseases
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: The following patients with chronic hepatitis C were eligible to enter the trial. 1) 20 years-old or older 2) HCV genotype 2a/2b or genotype 1b and HCV RNA <100 KIU/mL 3) Laboratory test at entry: 1. Neutrophil count >=1,500/mm3 2. Platelet count >=90,000/mm3 3. Hemoglobin concentration >= 10 g/dL 4) Patients who provided written informed consent to participate the study prior to enrollment
Exclusion criteria
Exclusion criteria: The following patients were excluded. 1. Concomitant herbal medication of Sho-saiko-to 2. Autoimmune hepatitis, alcoholic liver injury, or chronic liver diseases with other underlying causes 3. Allergic to pegylated interferon alpha-2a or other interferon preparations 4. Allergic to vaccine or biological preparations 5. Liver cirrhosis, decompensated liver disease, hepatocellular carcinoma, or other malignant diseases 6. Depression or psychiatric disorders 7. Other conditions considered inappropriate by attending physician
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Negative results of qualitative HCV RNA test at 24 weeks after terminating therapy | — |
Countries
Japan
Contacts
Public ContactYoshiaki Iwasaki
Okayama University Hospital Department of Gastroenterology and Hepatology
Outcome results
None listed